Stockreport

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics, Inc.  (CADL) 
PDF On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, ex [Read more]